Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine 2022-12-01 21:00
BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021 2022-11-16 21:00
Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development 2022-06-15 20:00
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement 2022-05-18 20:00
BioVaxys Expands Cancer Vaccine Platform 2022-03-30 16:02
BioVaxys Announces Bioproduction of BVX-1021 for its Pan-Sarbecovirus Program in Collaboration with The Ohio State University 2022-03-17 20:18
BIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein 2022-02-16 21:00
BioVaxys Further Expands Intellectual Property Portfolio in Global Markets 2021-10-28 20:00
BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine 2021-10-20 21:24
BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission 2021-09-28 20:00
BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins 2021-09-23 15:00
BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone 2021-09-17 15:00
BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs 2021-09-14 15:00
Further Study in humans shows that the DTH response, the basis for CoviDTH, is highly durable and persists for at least one year after COVID-19 exposure or vaccine administration 2021-09-07 20:00
Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans 2021-08-03 20:00
FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH 2021-07-22 21:50
BioVaxys Announces Non-Brokered Private Placement 2021-06-29 10:46
BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development 2021-06-15 04:19
BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study 2021-06-01 20:00
Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing 2021-05-24 20:00
1 2